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Objective. To examine whether the citrullinated
chemokines epithelial neutrophil–activating peptide 78
(ENA-78)/CXCL5, macrophage inflammatory protein
1/CCL3, and monocyte chemotactic protein 1/CCL2
are detected in the biologic fluid of patients with rheu-
matoid arthritis (RA), and if so, to determine the bio-
logic activities of these chemokines.
Methods. Recombinant human chemokines were
citrullinated by peptidylarginine deiminase. Enzyme-
linked immunosorbent assays were performed to mea-
sure the concentrations of citrullinated chemokines in
sera from patients with rheumatoid arthritis (RA) and
normal individuals and in synovial fluid from patients
with RA, patients with osteoarthritis (OA), and patients
with other inflammatory rheumatic diseases. The cor-
relation between the citrullinated chemokine levels and
clinical data was analyzed. Monocyte and neutrophil
chemotaxis assays were performed, and native (non-
citrullinated) or citrullinated ENA-78/CXCL5 was in-
jected into mouse knees to evaluate the biologic activi-
ties of these chemokines.
Results. The concentration of citrullinated ENA-
78/CXCL5 was significantly higher in RA sera and SF
than in normal sera and in SF from patients with other
rheumatic diseases including OA. In RA SF, a strong
correlation between the amount of citrullinated ENA-
78/CXCL5 and the C-reactive protein level or the eryth-
rocyte sedimentation rate was observed. Citrullinated
ENA-78/CXCL5 induced monocyte chemotaxis via
CXCR1 and CXCR2, while noncitrullinated ENA-78/
CXCL5 did not. In a mouse model of inflammatory
arthritis, citrullinated ENA-78/CXCL5 induced more
severe inflammation and recruited more monocytes
than did noncitrullinated ENA-78/CXCL5.
Conclusion. Citrullinated ENA-78/CXCL5 is
highly correlated with RA disease activity and, unlike
noncitrullinated ENA-78/CXCL5, recruits monocytes.
These results indicate that citrullinated ENA-78/CXCL5
may exert previously unrecognized inflammatory prop-
erties in RA by recruiting monocytes to inflamed joint
tissue.
Rheumatoid arthritis (RA) is a chronic inflam-
matory disorder characterized by the infiltration of
inflammatory cells into synovial tissue and synovial fluid
(SF) (1). Anti–cyclic citrullinated peptide (anti-CCP)
antibodies are present in the sera of nearly 70% of
patients with RA and have become key diagnostic
markers for this disease (2). Citrulline residues in target
antigens are essential in the formation of anti–
citrullinated peptide/protein antibody epitopes (3,4).
These epitopes result from citrullination, a posttransla-
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tional modification of arginine. Peptidylarginine deimi-
nase (PAD) enzymes are calcium-dependent enzymes
that catalyze citrullination of target proteins by convert-
ing arginine to citrulline (5). Five PAD family members,
PAD type 1 (PAD1), PAD2, PAD3, PAD4, and PAD6,
have been identified in many types of tissue, including
synovial tissue, and in human leukocytes (6).
Chemokines play an important role as monocyte
and polymorphonuclear neutrophil (PMN) recruiters in
the setting of RA synovitis and tissue destruction (7,8).
Chemokines are classified into 4 subfamilies based on
the number and spacing of their first cysteine residues in
the primary amino acid sequence (9). These chemokine
families are designated as CXC, CC, C, and CX3C. The
CXC chemokines are further divided into 2 subgroups
based on whether the Glu-Leu-Arg (ELR) motif pre-
cedes the first cysteine residue. Epithelial neutrophil–
activating peptide 78 (ENA-78)/CXCL5, a CXC chemo-
kine, is an 8.3-kd protein with 78 amino acids containing
4 cysteine residues positioned identically to those of
interleukin-8 (IL-8/CXCL8) (10). We previously ob-
served that the concentration of ENA-78/CXCL5, which
is associated with neutrophil recruitment, is significantly
higher in RA SF compared with osteoarthritis (OA) SF
or SF from patients with other forms of arthritis (11). In
addition, we demonstrated that neutralization of ENA-
78/CXCL5 ameliorated the severity of adjuvant-induced
arthritis in a rat model (12). These findings support the
notion that ENA-78/CXCL5 is important in the patho-
genesis of RA.
Although the presence of citrullinated proteins
such as fibrinogen, -enolase, and vimentin in RA has
been reported (4,13–15), citrullinated chemokines have
not yet been detected in RA. We chose to examine
chemokines, because they are biologically relevant joint
proteins. Several chemokines are highly expressed in the
joints of patients with RA, and PAD2 and PAD4 are
mainly present in synovial tissue. The expression levels
of these PADs are correlated with inflammation, thick-
ness of the synovial lining layer, and vascularity (16).
These observations support the hypothesis that citrulli-
nated chemokines may be present in rheumatic joints.
We compared the presence of citrullinated ENA-
78/CXCL5, citrullinated macrophage inflammatory pro-
tein 1 (MIP-1)/CCL3, and citrullinated monocyte
chemotactic protein 1 (MCP-1)/CCL2 in the biologic
fluid of patients with RA with that in the biologic fluid of
patients with other arthritic diseases, using a newly devel-
oped enzyme-linked immunosorbent assay (ELISA) sys-
tem, and examined the biologic activity of these chemo-
kines in vitro and that of ENA-78/CXCL5 in vivo.
PATIENTS AND METHODS
Patients and normal control subjects. Serum samples
were obtained from 11 patients with RA and 15 normal control
subjects, and SF samples were obtained from 20 patients with
RA, 15 patients with OA, and 13 patients with other inflam-
matory rheumatic diseases, including gout (n 4), pseudogout
(n  2), psoriatic arthritis (n  1), spondyloarthritis (n  3),
Behc¸et’s disease (n  1), Lyme disease (n  1), and unclassi-
fied arthritis (n 1). Rheumatoid factor (RF) was immunode-
pleted from RA sera and SF using goat anti-human IgM
(-chain specific) agarose (Sigma-Aldrich) prior to measuring
citrullinated chemokines by ELISA. All samples were obtained
after approval by the Institutional Review Board and provision
of informed consent by the subjects.
Chemokine DNA cloning. Full-length ENA-78/CXCL5
complementary DNA (cDNA) (NCBI accession no.
NM_002994) was obtained from Open Biosystems. We gener-
ated cDNA libraries for MCP-1/CCL2 and MIP-1/CCL3
from primary synovial fibroblasts derived from patients with
RA. The cDNA fragments encoding mature proteins were
amplified by polymerase chain reaction (PCR) using primers
with an incorporated Nco I restriction site in the forward
primers and with 6 codons encoding histidines followed by a
stop codon and the Eco RI restriction site in the reverse
primers (Primer Express software; Applied Biosystems). The
primers used are as follows (forward and reverse, respectively):
for ENA-78/CXCL5, 5-TAATCCATGGGAGCTGGTCCT-
GCCGCTGCTGT-3 and 5-TAAGAATTCTCAGTGATG-
GTGATGGTGATGGTTTTCCTTGTTTCCACCGT-3; for
MIP-1/CCL3, 5-TAATCCATGGGAGCTGACACGCCG-
ACCGCCTG-3 and 5-TAAGAATTCTCAGTGATGGTG-
ATGGTGATGGGCACTCAGCTCCAGGTCGC-3; for
MCP-1/CCL2, 5-TAATCCATGGGACAGCCAGATGCAA-
TCAATGCC-3 and 5-TAAGAATTCTCAGTGATGGTG-
ATGGTGATGAGTCTTCGGAGTTTGGGTTTG-3. Nco
I/Eco RI–flanked PCR fragments containing a C-terminus
6His tag were initially cloned into a pQE-TriSystem Vector
(Qiagen). All sequences were verified using BigDye Termina-
tor sequencing (Life Technologies). For optimization of mam-
malian expression, inserts containing a C-terminus 6His tag
were further cloned into the mammalian expression vector
pcDEF (17).
Transfection of HEK 293T cells and purification of
recombinant human chemokines. All mammalian expression
vectors were transfected into HEK 293T cells using polyethyl-
enimine (Polysciences) to collect 6His-tagged chemokines
from cellular lysates prepared with 1% Triton X-100. Chemo-
kines (6His tagged) from HEK 293T cell lysates were
purified with ProBond Nickel beads (Life Technologies),
rinsed extensively with 10 mM imidazole, and eluted gradually
with 50–200 mM imidazole. The quality and quantity of
expressed recombinant proteins were assessed with appropri-
ate DuoSet ELISA kits (R&D Systems) specific for these
proteins and with colloidal Coomassie staining after sodium
dodecyl sulfate–polyacrylamide gel electrophoresis resolution.
In vitro citrullination of chemokines. After the con-
centration of purified chemokines was measured using DuoSet
ELISA kits, 100 microliters of purified recombinant human
chemokine (100 ng/ml) was incubated with 0.5 units of rabbit
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skeletal muscle PAD (Sigma-Aldrich) in 40 mM Tris HCl, pH
7.6, 10 mM CaCl2, and 2.5 mM dithiothreitol for 2 hours at
37°C. Deimination was stopped by chelating the calcium with
25 mM EDTA. These citrullinated chemokines were subse-
quently used as standards for ELISA of citrullinated chemo-
kines. Alternatively, 5 M recombinant human ENA-78
(rhENA-78)/CXCL5, recombinant human MIP-1/CCL3, or
recombinant human MCP-1/CCL2 (OriGene) was incubated
with rabbit skeletal PAD (250 nM) at enzyme:substrate molar
ratios of 1:20 in 40 mM Tris HCl with 2 mM CaCl2 (pH 7.4) for
1.5 hours at 37°C. Deimination was stopped with 0.1% trifluo-
roacetic acid (TFA). These citrullinated chemokines were used
in both in vitro chemotaxis assays and in vivo experiments.
Citrullination of rhENA-78/CXCL5 was confirmed by Western
blotting (18). For detection of citrullinated protein, citrulline
residues were chemically modified to form a ureido group
adduct before addition of an anti–modified citrulline antibody
(Millipore) according to the manufacturer’s protocol, which
enables detection of citrulline residues independent of neigh-
boring amino acid sequences (19). The diagnostic 1Da mass
shift occurring upon citrullination was identified by liquid
chromatography tandem mass spectrometry (MS Bioworks)
(20).
Sandwich ELISA for citrullinated chemokines. An
ELISA was designed to determine the concentrations of
citrullinated chemokines in biologic fluid. Ninety-six–well
plates (Thermo Fisher Scientific) were coated overnight at
room temperature with mouse anti-human ENA-78/CXCL5,
mouse anti-human MCP-1/CCL2, or goat anti-human MIP-1/
CCL3 (R&D Systems). Between each step, the plates were
washed with wash buffer (0.05% Tween 20 in phosphate
buffered saline [PBS]). The plates were blocked with 1%
bovine serum albumin (BSA) in PBS for 1 hour at room
temperature and incubated with serum, SF, or standards for 2
hours at room temperature. Citrullinated recombinant human
chemokines and native (noncitrullinated) recombinant human
chemokines purified from the transfected HEK 293T cells
were used as standards and negative controls, respectively, for
the ELISA. The samples were crosslinked onto the plates with
1% glutaraldehyde in PBS for 30 minutes at room tempera-
ture.
The plates were then incubated with 0.2M Tris HCl
(pH 7.8) for 30 minutes at room temperature to block the
crosslinking. The plates were then incubated overnight at 37°C
in a citrulline-modification solution consisting of 2 parts solu-
tion A (0.025% [weight/volume] FeCl3, 4.6M H2SO4, and 3.0M
H3PO4), 1 part solution B (1% diacetylmonoxime, 0.5%
antipyrine, and 1M acetic acid), and 1 part H2O (18). The
plates were incubated for 2 hours at room temperature with
rabbit anti–modified citrulline (Millipore), diluted 1:2,500 in
PBS containing 1% BSA. The plates were incubated for 2
hours at room temperature with horseradish peroxidase
(HRP)–conjugated swine anti-rabbit IgG (Dako), diluted
1:1,000 in PBS containing 1% BSA. Biotin-Tyramide Reagent
(PerkinElmer), diluted 1:1,000 in 0.05M Tris (base pH 8.5),
was added, followed by HRP-conjugated streptavidin. The
plates were developed using tetramethylbenzidine, develop-
ment was stopped with 2N H2SO4, and the plates were read on
a microplate reader at 450 nm. Serum and SF chemokine
concentrations were also measured using DuoSet ELISA kits.
In vitro monocyte and polymorphonuclear neutrophil
(PMN) chemotaxis assays. Monocytes and PMNs were iso-
lated from normal human peripheral blood. Monocyte and
PMN chemotaxis assays were performed using 48-well modi-
fied Boyden chambers (Neuro Probe) as described previously
(21,22). Noncitrullinated chemokines (OriGene), citrullinated
chemokines, and reaction buffer consisting of 40 mM Tris HCl,
2 mM CaCl2, 250 nM rabbit skeletal PAD, and 0.1% TFA were
diluted by PBS with calcium and magnesium in the same
manner and tested for chemotaxis. The composition of the
reaction buffer that contained PAD enzymes was the same as
the composition of the stock solution of citrullinated chemo-
kines. PBS with calcium and magnesium and fMLP (100 nM)
(Sigma-Aldrich) were used as negative and positive stimuli,
respectively. For the inhibitor studies, monocytes (2.5 
106/ml) were pretreated with 500 ng/ml pertussis toxin (Sigma-
Aldrich), which is a G protein–coupled receptor antagonist, 10
g/ml anti-CXCR1, anti-CXCR2, or isotype control IgG2a
(R&D Systems) in PBS with calcium and magnesium for 1
hour to examine whether G protein–coupled receptors are
used by citrullinated ENA-78/CXCL5 to induce monocyte
chemotaxis.
Mouse model of inflammatory arthritis. Female
C57BL/6 mice (8–10 weeks old) were purchased from the
National Cancer Institute. The mice were divided into the
following 3 treatment groups: PBS, noncitrullinated ENA-78/
CXCL5 (Origene), and citrullinated ENA-78/CXCL5. The
mice were anesthetized, and the knee circumference was
determined by caliper measurements before intraarticular
injection and calculated using the following formula: circum-
ference   (a  b)/2, where a is the laterolateral diameter
and b is the anteroposterior diameter. The anesthetized mice
received 20 l/knee joint of PBS, noncitrullinated ENA-78/
CXCL5 (16 ng), or citrullinated ENA-78/CXCL5 (16 ng). In all
of the mice, circumference measurements were obtained in a
blinded manner 24 hours after the intraarticular injection.
Hematoxylin and eosin (H&E) and immunofluores-
cence staining. Mouse knee joints embedded in OCT com-
pound were frozen and cut (10 m). H&E staining was
performed as described previously (23). Immunofluorescence
staining was performed on cryosections from mouse knee
joints to determine monocyte/macrophages, using rat anti-
mouse F4/80 antibodies (GeneTex) at 1 g/ml as primary
antibody and Alexa Fluor 555–conjugated goat anti-rat IgG
(Life Technologies) at a dilution of 1:200 as secondary anti-
body. The method of immunofluorescence staining has been
described previously (21). The number of F4/80-positive
monocyte/macrophages was calculated as the average of the
number of cells in 3 fields (400) that showed the most
remarkable infiltrates in the joint space where the injections
were administered.
Statistical analysis. Statistical differences between ex-
perimental groups were determined by Student’s t-test or
one-way analysis of variance followed by Tukey’s multiple
comparison test for post hoc analysis. The clinical correlation
between chemokine levels and clinical data was assessed by
Pearson’s correlation coefficient. Statistical analysis was per-
formed with assistance from personnel at the Center for
Statistical Consultation and Research at the University of
Michigan. Results are expressed as the mean  SEM. P values
less than 0.05 were considered significant.
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RESULTS
Detection of citrullinated rhENA-78/CXCL5 and
verification of in vitro citrullination of ENA-78/CXCL5.
As shown in Figure 1A, the standard curve of citrulli-
nated rhENA-78/CXCL5, as determined by ELISA,
demonstrated high correlation between the concentra-
tion of citrullinated rhENA-78/CXCL5 and absorbance
(Figure 1A). Noncitrullinated ENA-78/CXCL5 (1000
pg/ml) was not detected by this ELISA. We then per-
formed Western blotting to confirm that rhENA-78/
CXCL5 was citrullinated in vitro. Citrullinated ENA-78/
CXCL5 was recognized by anti–modified citrulline
antibody, while noncitrullinated ENA-78/CXCL5 was
not (Figure 1B). The diagnostic 1Da mass shift occur-
ring upon citrullination of ENA-78/CXCL5, which has 2
arginine residues, was identified by mass spectrometry
(20). The mass spectrometry data indicated that both
arginine residues were detected and citrullinated (Fig-
ures 1C and D). Citrullination of MCP-1/CCL2 and
MIP-1/CCL3, which have 4 and 3 arginine residues,
respectively, was also identified by mass spectrometry
(data not shown).
Citrullinated chemokine concentrations in RA
sera and normal control sera. To ascertain whether
citrullinated chemokines were detectable in biologic
fluids, we assayed serum samples obtained from patients
with RA and normal control subjects, using a citrulli-
nated chemokine sandwich ELISA. In normal control
subjects and patients with RA, the mean  SEM levels
of citrullinated ENA-78/CXCL5 were 1.2  0.7 pg/ml
and 286  68 pg/ml, respectively (Figure 2A). The levels
of citrullinated MIP-1/CCL3 in normal and RA sera
were 1.2  1.2 pg/ml and 624  96 pg/ml, respectively
(Figure 2B), and the levels of citrullinated MCP-1/CCL2
in normal and RA sera were 0.9  0.5 pg/ml and 143 
18 pg/ml, respectively (Figure 2C). The levels of citrul-
linated ENA-78/CXCL5, MIP-1/CCL3, and MCP-1/
CCL2 in patients with RA were all significantly higher
than the levels in normal control subjects (P  0.05).
The mean  SEM concentrations of ENA-78/CXCL5
Figure 1. Detection of citrullinated recombinant human epithelial neutrophil–activating peptide 78 (ENA-78)/CXCL5 and verification of successful
in vitro citrullination of ENA-78/CXCL5. A, Standard curve of citrullinated recombinant human ENA-78/CXCL5 as determined by enzyme-linked
immunosorbent assay. Each point was determined using duplicate assays. B, Immunoblots showing that citrullinated recombinant human
ENA-78/CXCL5 was recognized by anti–modified citrulline antibody (right) while noncitrullinated ENA-78/CXCL5 was not (left). The blot used to
detect citrullinated protein was chemically modified prior to immunostaining. C, Amino acid sequence of ENA-78/CXCL5 (mature form 37–114).
The boxed areas show the citrullinated arginines that were detected. D, Annotated tandem mass spectrometry (MS/MS) fragmentation spectra for
the citrullinated ENA-78/CXCL5 peptides, showing the citrullinated arginine residues. Left, MS/MS spectrum confirming the presence of C-terminal
citrullination at position 12 (R48) from the y1 and y2 ions present in the spectrum. Right, The presence of ions y4 to y9 in the spectrum confirms
the presence of the “middle” R1 (citrullination) at position 9 (R45). The MS/MS fragmentation data were annotated using Expert System
(Max-Planck Institute of Biochemistry). The precursor ion was observed with a mass error of 1 parts per million, and the error for the fragment
ions was 0.02 daltons.
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were 3,165 825 pg/ml in normal sera and 3,942 1,139
pg/ml in RA sera, the levels of MIP-1/CCL3 were
230  176 pg/ml and 727  420 pg/ml, respectively, and
the levels of MCP-1/CCL2 were 43  22 pg/ml and
289  271 pg/ml, respectively; none of the differences
between groups were statistically significant (results not
shown).
Citrullinated chemokine concentrations in SF
from patients with RA, patients with OA, and patients
with other rheumatic diseases. The concentrations of
citrullinated chemokines in SF samples obtained from
patients with RA, patients with OA, and patients with
other inflammatory rheumatic diseases were measured
by sandwich ELISA. The mean SEM concentration of
citrullinated ENA-78/CXCL5 was significantly higher
in SF from patients with RA (1,126 297 pg/ml) than in
SF from patients with OA (2.3 1.0 pg/ml) and patients
with other inflammatory rheumatic diseases (15  9
pg/ml) (P  0.05) (Figure 2D). The mean  SEM
concentration of citrullinated MIP-1/CCL3 was also
significantly higher in the SF of patients with RA (755
152 pg/ml) compared with that in the SF of patients with
other inflammatory rheumatic diseases (109 49 pg/ml)
and patients with OA (9  15 pg/ml) (P  0.05) (Figure
2E). Citrullinated MCP-1/CCL2 concentrations were
significantly higher in RA SF (14  2 pg/ml) compared
with OA SF (1.6  0.7 pg/ml) (P  0.05) (Figure 2F).
We also used ELISA kits to measure chemokine
concentrations. The mean  SEM concentrations of
ENA-78/CXCL5 were 163  107 pg/ml in RA SF, 0  0
pg/ml in the SF of patients with other diseases, and 19
13 pg/ml in OA SF. The concentrations of MIP-1/
CCL3 were 460  171 pg/ml in RA SF, 31  10 pg/ml in
SF from patients with other rheumatic diseases, and
75  52 pg/ml in OA SF. The concentrations of MCP-
1/CCL2 were 1,085  398 pg/ml in RA SF, 288  42
pg/ml in SF from patients with other rheumatic diseases,
and 390  80 pg/ml in OA SF. There were no significant
differences in SF chemokine concentrations between
these groups.
Positive correlation between citrullinated ENA-
78/CXCL5 concentrations and the C-reactive protein
(CRP) level and erythrocyte sedimentation rate (ESR)
in RA SF. We analyzed the relationship between the
citrullinated chemokine concentrations in SF and clini-
cal data in patients with RA. As shown in Table 1, the
clinical characteristics of these patients were as follows:
mean  SEM age 52.7  3.4 years, disease duration
145.7  39.2 months, ESR 38.1  4.3 mm/hour, CRP
level 40.5  9.9 mg/liter, Disease Activity Score in 28
Figure 2. Expression of citrullinated chemokines in rheumatoid arthritis (RA) sera and synovial fluid (SF). Citrullinated chemokines were
measured using an enzyme-linked immunosorbent assay (ELISA) in which chemokines were captured on an ELISA plate, followed by detection with
anti–modified citrulline after chemical modification of citrulline residues. Rheumatoid factor was depleted from RA SF and RA sera prior to the
ELISA. A–C, Concentrations of citrullinated epithelial neutrophil–activating peptide 78 (ENA-78)/CXCL5 (A), macrophage inflammatory protein
1 (MIP-1)/CCL3 (B), and monocyte chemotactic protein 1 (MCP-1)/CCL2 (C) in normal sera and sera from patients with RA. D–F,
Concentrations of citrullinated ENA-78/CXCL5, citrullinated MIP-1/CCL3, and citrullinated MCP-1/CCL2 in SF from patients with other
inflammatory rheumatic diseases (OD), patients with osteoarthritis (OA), and patients with RA. Bars show the mean  SEM.
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joints (24) 5.1  0.4, tender joint count 5.7  2.1,
swollen joint count 4.5  1.9, RF level 74.8  43.2
units/ml, and anti-CCP antibody level 2,296.1  1,559.1
AU/ml. As shown in Figure 3, citrullinated ENA-78/
CXCL5 concentrations were significantly correlated
with CRP levels (r  0.69, P  0.05) and the ESR (r 
0.77, P  0.05), and citrullinated MCP-1/CCL2 concen-
trations were significantly correlated with the ESR (r 
0.64, P  0.05). There was no significant correlation
between the concentration of citrullinated MIP-1/CCL3
in RA SF with the other clinical parameters examined.
Citrullinated ENA-78/CXCL5–induced monocyte
migratory activity via CXCR1 and CXCR2. Under nor-
mal conditions, ENA-78/CXCL5 induces PMN migra-
tion, but it does not induce monocyte migration (10,25,26).
We performed monocyte and PMN chemotaxis assays
using a modified Boyden chamber, and the results
showed that the fold increase in monocyte migration was
significantly higher in response to citrullinated ENA-78/
CXCL5 at 0.1 nM, 1 nM, and 10 nM (mean SEM 1.6
0.1, 1.9  0.2, and 1.9  0.2, respectively) than in
response to noncitrullinated ENA-78/CXCL5 and PBS
(Figure 4A). We also tested various concentrations of
reaction buffer in citrullinated ENA-78/CXCL5 stock
solution for chemotaxis of monocytes. The reaction
buffer including PAD enzymes did not induce monocyte
migration at the concentrations tested. In contrast to
citrullinated ENA-78/CXCL5, citrullinated MCP-1/
CCL2 recruited significantly fewer monocytes at 10 nM
and 100 nM than did noncitrullinated MCP-1/CCL2
(data not shown), and citrullinated MIP-1/CCL3
tended to have the same level of monocyte-recruiting
activity as noncitrullinated MIP-1/CCL3 at 0.01–100
nM (data not shown).
PMN chemotaxis assays showed that noncitrulli-
nated ENA-78/CXCL5 had significantly higher PMN
chemotactic activity at 0.1 nM (1.5  0.2) and 1 nM
(1.6  0.2) compared with PBS (P  0.05), while
citrullinated ENA-78/CXCL5 had significantly higher
activity at 10 nM (1.4  0.1) compared with PBS (P 
0.05) (Figure 4B). Thus, the fold increase in PMN
Figure 3. Correlation of clinical data with citrullinated chemokine
levels in RA SF. Positive correlations between citrullinated ENA-78/
CXCL5 and the C-reactive protein (CRP) level (A), citrullinated
ENA-78/CXCL5 and the erythrocyte sedimentation rate (ESR) (B),
and citrullinated MCP-1/CCL2 and the ESR (C) were observed. See
Figure 2 for other definitions.
Table 1. Clinical characteristics of the patients with rheumatoid
arthritis whose synovial fluid was studied*
Male/female, % (n  20) 20/80
Age, years (n  20) 52.7  3.4
Disease duration, months (n  20) 145.7  39.2
Tender joint count in 28 joints (n  13) 5.7 2.1
Swollen joint count in 28 joints (n  13) 4.5 1.9
Bone erosion, yes/no, % (n  20) 40/60
ESR, mm/hour (n  15) 38.1  4.3
CRP, mg/liter (n  14) 40.5  9.9
DAS28 (n  12) 5.1  0.4
Rheumatoid factor, units/ml (n  10) 74.8  43.2
Anti-CCP, AU/ml (n  10) 2,296.1 1,559.1
* Except where indicated otherwise, values are the mean SEM. ESR
 erythrocyte sedimentation rate; CRP  C-reactive protein; DAS28
 Disease Activity Score in 28 joints; anti-CCP  anti–cyclic citrulli-
nated peptide.
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migration in response to citrullinated ENA-78/CXCL5
tended to be lower than that in response to noncitrulli-
nated ENA-78/CXCL5. However, there was no signifi-
cant difference in PMN chemotaxis between noncitrul-
linated and citrullinated ENA-78/CXCL5.
In monocyte chemotaxis assays using pertussis
toxin (a G protein–coupled receptor antagonist), anti-
CXCR1, and anti-CXCR2 antibodies, the fold increase
in the response to citrullinated ENA-78/CXCL5 with
pertussis toxin was significantly lower (mean  SEM
1.07  0.06) compared with that without pertussis toxin
(2.06  0.14; P  0.05) (Figure 4C). We then examined
whether monocyte migration is mediated via the G
protein–coupled receptors CXCR1 and CXCR2. The
fold increases in the response to citrullinated ENA-78/
CXCL5 with anti-CXCR1 or anti-CXCR2 antibodies
were significantly lower (1.34  0.04 and 1.55  0.05,
respectively) compared with that without the antibodies
(2.05  0.07), and the fold increase in the response to
citrullinated ENA-78/CXCL5 with a combination of
anti-CXCR1 and anti-CXCR2 antibodies was signifi-
cantly lower (1.02  0.03) compared with that without
the antibodies, with anti-CXCR1, or with anti-CXCR2
(P  0.05). IgG2a was used as an isotype-matched
control monoclonal antibody that did not inhibit mono-
cyte migration (Figure 4D). These results indicated that
citrullinated ENA-78/CXCL5 induced monocyte migra-
tion via CXCR1 and CXCR2.
Citrullinated ENA-78/CXCL5–enhanced induc-
tion of inflammatory arthritis and recruitment of
monocyte/macrophages in vivo. To test the inflamma-
tory activity of citrullinated ENA-78/CXCL5 in vivo, we
Figure 4. Monocyte recruitment by citrullinated epithelial neutrophil–activating peptide 78 (ENA-78)/CXCL5. A, Fold increase in monocyte
migration in response to citrullinated ENA-78/CXCL5 and noncitrullinated ENA-78/CXCL5, as determined by monocyte chemotaxis assay. At 0.1
nM, 1 nM, and 10 nM , the response to citrullinated ENA-78/CXCL5 was significantly higher than the response to noncitrullinated ENA-78/CXCL5
and phosphate buffered saline (PBS). As controls, various concentrations of reaction buffer including peptidylarginine deiminase enzymes were
tested for chemotaxis of monocytes. There was no significant difference between the response to reaction buffer and the response to PBS. The
mean  SEM fold increase in monocyte migration in response to fMLP (100 nM) was 4.4  0.5. B, Fold increase in polymorphonuclear neutrophil
(PMN) migration in response to citrullinated ENA-78/CXCL5 and noncitrullinated ENA-78/CXCL5, as determined by chemotaxis assay. At either
0.1 nM or 1 nM, the response to noncitrullinated ENA-78/CXCL5 was significantly higher than the response to PBS (P  0.05). The response to
citrullinated ENA-78/CXCL5 was lower than the response to noncitrullinated ENA-78/CXCL5, but the difference was not significant. The mean 
SEM fold increase in PMN migration in response to fMLP (100 nM) was 7.5  2.5. C, Effect of pertussis toxin (PTX) on the increased monocyte
migration in response to citrullinated ENA-78/CXCL5. D, Effect of anti-CXCR1 (anti-R1) and anti-CXCR2 (anti-R2) on the increased monocyte
migration in response to citrullinated ENA-78/CXCL5. All assays were performed in quadruplicate, with 3 high-power fields (400) counted in each
replicate well. The fold increase was determined by dividing the number of cells migrated by the number of cells migrated to the negative control
PBS. Values are the mean  SEM.
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injected PBS, noncitrullinated ENA-78/CXCL5, or cit-
rullinated ENA-78/CXCL5 into mouse knee joints.
Joints injected with citrullinated ENA-78/CXCL5 had a
significantly greater increase in circumference (mean 
SEM 3.0 0.3 mm), and hence joint swelling, compared
with knees injected with PBS (0.4  0.2 mm; P  0.05)
or noncitrullinated ENA-78/CXCL5 (1.7  0.3 mm; P 
0.05). Joints injected with noncitrullinated ENA-78/
CXCL5 had significantly increased joint swelling com-
pared with joints injected with PBS (P  0.05) (Figure
5A). H&E staining showed inflammatory cell infiltration
in each treatment group, and inflammation was espe-
cially severe in the group that received citrullinated
ENA-78/CXCL5 (Figure 5B). Immunofluorescence
staining revealed that the number of F4/80-positive
monocyte/macrophages was significantly higher in
mouse knee joints injected with citrullinated ENA-78/
CXCL5 (mean  SEM 67  7 macrophages) compared
with joints injected with noncitrullinated ENA-78/
CXCL5 (40  3 macrophages) or PBS (21  4 macro-
phages). In addition, the number of F4/80-positive
monocyte/macrophages was significantly higher in the
mice treated with noncitrullinated ENA-78/CXCL5
compared with those that received PBS (P  0.05)
(Figures 5B and C).
DISCUSSION
We observed the presence of citrullinated ENA-
78/CXCL5, MIP-1/CCL3, and MCP-1/CCL2 in RA
sera and RA SF. There is evidence that some chemo-
kines can be citrullinated in vitro (27–30); however, not
all cytokines can be citrullinated. Proost et al showed
that PAD efficiently and site-specifically citrullinated
ENA-78/CXCL5 and IL-8/CXCL8 but not IL-1 (27).
Struyf et al demonstrated that stromal cell–derived
factor 1 (SDF-1)/CXCL12 can be citrullinated in vitro,
and that SDF-1/CXCL12 and PAD were coexpressed in
Figure 5. Effect of citrullinated ENA-78/CXCL5 in vivo. The knees of female C57BL/6 mice were injected intraarticularly with PBS,
noncitrullinated ENA-78/CXCL5, or citrullinated ENA-78/CXCL5 to induce inflammation. A, Circumference of the mouse knees 24 hours after
administration of the intraarticular injections. The increases in knee circumference were significantly greater in mice that received citrullinated
ENA-78/CXCL5 compared with those that received PBS or noncitrullinated ENA-78/CXCL5 and were also significantly greater in mice that
received noncitrullinated ENA-78/CXCL5 compared with those that received PBS. B, Left, Hematoxylin and eosin (H&E)–stained mouse knee joint
sections, showing inflammatory cell infiltration in all groups and severe inflammation in mice treated with citrullinated ENA-78/CXCL5. Right,
Immunofluorescence-stained mouse knee joint sections, showing a greater number of F4/80-positive monocyte/macrophages in mice treated with
citrullinated ENA-78/CXCL5. Fluorescent red and blue staining show F4/80-positive monocyte/macrophages and cell nuclei, respectively. Original
magnification  400. C, Numbers of F4/80-positive monocyte/macrophages in mice treated with PBS, noncitrullinated ENA-78/CXCL5, and
citrullinated ENA-78/CXCL5. Values are the mean  SEM (n values are the number of joints). See Figure 4 for other definitions.
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the colon tissue of patients with Crohn’s disease (30).
However, those investigators did not directly demon-
strate the presence of citrullinated SDF-1/CXCL12 in
diseased colon tissue.
In the current study, we demonstrated that the
concentrations of citrullinated ENA-78/CXCL5, MIP-
1/CCL3, and MCP-1/CCL2 were all significantly higher
in RA sera than in normal control sera. Furthermore,
citrullinated ENA-78/CXCL5 and MIP-1/CCL3 con-
centrations were significantly higher in RA SF than in
SF from patients with OA and patients with other
rheumatic diseases, and the level of citrullinated MCP-
1/CCL2 was significantly higher in RA SF than in OA
SF. In particular, the concentration of citrullinated
ENA-78/CXCL5 was high in RA SF but was barely
detected in SF from patients with OA or other rheu-
matic diseases. Additionally, the PAD4 level measured
by ELISA is significantly elevated in RA SF compared
with SF from patients with OA and patients with anky-
losing spondylitis (31). This fact supports the notion that
chemokines, including ENA-78/CXCL5, are citrulli-
nated more efficiently in RA joints than in the inflamed
joints of patients with other diseases. In our study, the
concentrations of ENA-78/CXCL5 and MIP-1/CCL3
in SF as measured by standard ELISA kits (R&D
Systems) were lower than the concentrations of citrulli-
nated ENA-78/CXCL5 and MIP-1/CCL3 in SF as
measured by the new ELISA system developed by our
group. We observed that after citrullination, purified
chemokines were not detected by standard ELISAs
(data not shown). It is possible that these ELISAs may
not completely recognize citrullinated chemokines in
RA SF.
We showed that among 3 citrullinated chemo-
kines tested in RA SF, the concentrations of citrulli-
nated ENA-78/CXCL5 correlated most closely with clin-
ical data (the CRP level and the ESR). Chemokines are
readily detectable in RA SF (11,32–36), and the concen-
trations of MIP-1/CCL3 and IL-8/CXCL8 in SF corre-
late with CRP levels in serum (35,36). In our study, we
observed significant positive correlations between citrul-
linated ENA-78/CXCL5 and not only the CRP level but
also the ESR, whereas the ENA-78/CXCL5 concentra-
tion did not correlate with any clinical parameters
examined (data not shown). These results suggest that
compared with the other chemokines that we examined,
citrullinated ENA-78/CXCL5 is more closely related to
disease activity in RA.
Citrullination has been reported to decrease the
activities of certain chemokines in some instances (37).
In vitro, ENA-78/CXCL5 (0.1–10 nM) induces PMN
migration in a dose-responsive manner (10,25). How-
ever, citrullination of ENA-78/CXCL5 has been re-
ported to reduce in vitro and in vivo PMN chemotaxis,
intracellular calcium signaling, phosphorylation of extra-
cellular signal–regulated kinase, and internalization of
CXCR2 compared with noncitrullinated ENA-78/
CXCL5 (38). We showed that citrullination of ENA-78/
CXCL5 directly supports monocyte migration but not
PMN migration. These results indicate the possibility
that citrullination of ENA-78/CXCL5 does not increase
the function of ENA-78/CXCL5 as a PMN recruiter but
instead dampens it.
Surprisingly, we observed that citrullinated ENA-
78/CXCL5 acquired a monocyte-recruiting function that
noncitrullinated ENA-78/CXCL5 did not have. Nor-
mally, ENA-78/CXCL5 is not a potent chemotactic
factor for monocytes but rather for PMNs and endothe-
lial cells and also possesses angiogenic properties
(10,25,39,40). Monocyte chemotaxis assays showed that
citrullinated ENA-78/CXCL5 recruited monocytes in a
dose-dependent manner, while noncitrullinated ENA-
78/CXCL5 did not. These results suggest that citrullina-
tion of ENA-78/CXCL5 results in its conversion from a
non–monocyte-recruiting chemokine to a monocyte-
recruiting chemokine.
We then investigated whether citrullinated ENA-
78/CXCL5 recruited monocytes through the G protein–
coupled receptors CXCR2, which is the primary ENA-
78/CXCL5 receptor, and CXCR1, which has 78%
homology with CXCR2 at the amino acid level (41,42).
Citrullinated ENA-78–induced monocyte migration was
completely inhibited by pertussis toxin (a G protein–
coupled receptor antagonist) or by a combination of
anti-CXCR1 and anti-CXCR2 antibodies. These results
suggest that citrullinated ENA-78/CXCL5 recruits
monocytes via both CXCR1 and CXCR2. ENA-78/
CXCL5 elicits PMN chemotaxis by interacting with the
chemokine receptor CXCR2 present on the PMN cell
surface (43,44). This receptor is expressed on many
different cells including PMNs and monocytes (45).
CXCR1 is also present on the surface of human mono-
cytes (26,46). CXCR1 and CXCR2 are expressed on
23–90% and 22–93% of human monocytes, respectively
(26). IL-8/CXCL8, neutrophil-activating peptide/
CXCL7, growth-related oncogene /CXCL1, and ENA-
78/CXCL5 bind to CXCR2 with high affinity, whereas
IL-8/CXCL8 exhibits high affinity for CXCR1 as well
(47,48). Our results suggest that citrullination may in-
crease the affinity of ENA-78/CXCL5 for CXCR1 (38).
We clearly show that at physiologically relevant
concentrations, citrullinated ENA-78/CXCL5 recruits
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monocytes. We also show data confirming that citrulli-
nated ENA-78/CXCL5 preferentially binds to the
CXCR1 receptor instead of the normal receptor for
ENA-78/CXCL5, namely CXCR2. This indicates that
modification of ENA-78/CXCL5 changes its receptor-
binding affinity (and likely its conformation). This also
explains, at least in part, the ability of citrullinated
ENA-78/CXCL5 to recruit monocytes. Nonetheless, as-
suming that both citrullinated ENA-78/CXCL5 and non-
citrullinated ENA-78/CXCL5 are present in SF and are
binding to the same receptor, the modified or unmodi-
fied forms of ENA-78/CXCL5 that are present in
greater quantities would be the forms that are more
competitive for binding the available receptor. However,
we now present evidence that citrullinated ENA-78/
CXCL5 utilizes an alternative receptor (CXCR1), indi-
cating that the concentration of citrullinated ENA-78/
CXCL5 is likely more important when considering the
monocyte-recruiting activity of citrullinated ENA-78/
CXCL5. We believe that the conversion of ENA-78/
CXCL5, a potent neutrophil recruitment factor to cit-
rullinated ENA-78/CXCL5, an active monocyte
recruitment factor, represents a change to a more
chronic inflammatory response in RA-affected joints.
Last, we examined whether citrullination of
ENA-78/CXCL5 results in increased inflammation and
monocyte migration in vivo compared with noncitrulli-
nated ENA-78/CXCL5. To test this hypothesis, we in-
jected noncitrullinated or citrullinated ENA-78/CXCL5
into mouse knee joints and evaluated joint inflammation
and monocyte migration. Citrullinated ENA-78/CXCL5
increased the knee circumference more than noncitrul-
linated ENA-78/CXCL5. Immunofluorescence staining
showed that citrullinated ENA-78/CXCL5 induced more
F4/80-positive monocyte/macrophage ingress into the
synovial tissue of mouse knees compared with noncitrul-
linated ENA-78/CXCL5. These results suggest that cit-
rullination of ENA-78/CXCL5 induces more severe in-
flammation in mouse knee joints through monocyte
recruitment.
In the current study, although RA sera and RA
SF were obtained from different groups of patients, the
concentration of citrullinated ENA-78/CXCL5 in RA SF
was higher than that in RA sera. These results suggest
that citrullinated ENA-78/CXCL5 may be produced
mainly in the joints and functions to recruit monocytes
to the joints. Other citrullinated proteins (e.g, citrulli-
nated vimentin) stimulate proinflammatoy cytokine pro-
duction from fibroblast-like synoviocytes or peripheral
blood mononuclear cells in RA (49,50). It is possible
that citrullinated ENA-78/CXCL5 may also stimulate
cells other than monocytes in mouse knee joints to
release inflammatory mediators and aggravate the in-
flammatory response.
In addition, our study demonstrated that non-
citrullinated ENA-78/CXCL5 recruited more monocyte/
macrophages in vivo compared with PBS. In general,
ENA-78/CXCL5 recruits neutrophils in vitro and in vivo.
However, it is possible that other types of cells besides
neutrophils respond to ENA-78/CXCL5 in vivo. It has
been reported that macrophages, which are either in-
flammatory monocyte-derived cells or reemerging
tissue-resident macrophages, increase in number during
acute inflammatory responses (51). It is quite possible
that the number of monocyte/macrophages increases in
vivo during ENA-78/CXCL5–induced acute inflamma-
tion.
In conclusion, citrullinated ENA-78/CXCL5 was
detected in RA SF and sera. The concentrations were
significantly higher in SF from patients with RA than in
SF from patients with OA or other inflammatory rheu-
matic diseases and correlated with the CRP level and the
ESR. Citrullinated ENA-78/CXCL5 induced monocyte
migration via CXCR1 and CXCR2 in vitro, while non-
citrullinated ENA-78/CXCL5 did not. Mouse knees
injected with citrullinated ENA-78/CXCL5 had more
inflammation and monocyte/macrophages than did
those injected with noncitrullinated ENA-78/CXCL5,
suggesting that citrullination enhances the proinflamma-
tory activity of ENA-78/CXCL5 and accelerates disease
progression in inflammatory arthritis.
ACKNOWLEDGMENTS
We thank Dr. David A. Fox (Division of Rheumatol-
ogy, University of Michigan Medical School) for helpful com-
ments and interpretation of the results; Dr. Henriette A.
Remmer (Proteomics & Peptide Synthesis Core, University of
Michigan Medical School) and Dr. Michael Ford (MS Bio-
works) for helpful comments on the mass spectrometry data
and for providing the spectra; and Ray A. Ohara (University of
Michigan) for assistance performing the experiments.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Yoshida had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Yoshida, Korchynskyi, Tak, Ruth,
Campbell, Amin, Koch.
Acquisition of data. Yoshida, Korchynskyi, Isozaki, Baeten, Gerlag,
Amin.
Analysis and interpretation of data. Yoshida, Korchynskyi, Ruth,
Campbell, Koch.
CITRULLINATED ENA-78/CXCL5 IN RHEUMATOID ARTHRITIS 2725
REFERENCES
1. Tak PP, Bresnihan B. The pathogenesis and prevention of joint
damage in rheumatoid arthritis: advances from synovial biopsy and
tissue analysis. Arthritis Rheum 2000;43:2619–33.
2. Van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies:
the past, the present and the future. Nat Rev Rheumatol 2011;7:
391–8.
3. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte
LB, van Venrooij WJ. Citrulline is an essential constituent of
antigenic determinants recognized by rheumatoid arthritis-specific
autoantibodies. J Clin Invest 1998;101:273–81.
4. Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L,
et al. Epitopes of human fibrin recognized by the rheumatoid
arthritis-specific autoantibodies to citrullinated proteins. Eur J Im-
munol 2006;36:2250–63.
5. Suzuki A, Yamada R, Yamamoto K. Citrullination by peptidy-
larginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci
2007;1108:323–39.
6. Mangat P, Wegner N, Venables PJ, Potempa J. Bacterial and
human peptidylarginine deiminases: targets for inhibiting the
autoimmune response in rheumatoid arthritis? Arthritis Res Ther
2010;12:209.
7. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine
receptors in rheumatoid arthritis. Semin Immunol 2003;15:15–21.
8. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease:
the key to inflammation? Ann Rheum Dis 2004;63:1186–94.
9. Zlotnik A, Yoshie O. Chemokines: a new classification system and
their role in immunity. Immunity 2000;12:121–7.
10. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter
RM. Structure and neutrophil-activating properties of a novel
inflammatory peptide (ENA-78) with homology to interleukin 8. J
Exp Med 1991;174:1355–62.
11. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK,
Burdick MD, et al. Epithelial neutrophil activating peptide-78: a
novel chemotactic cytokine for neutrophils in arthritis. J Clin
Invest 1994;94:1012–8.
12. Halloran MM, Woods JM, Strieter RM, Szekanecz Z, Volin MV,
Hosaka S, et al. The role of an epithelial neutrophil-activating
peptide-78-like protein in rat adjuvant-induced arthritis. J Immu-
nol 1999;162:7492–500.
13. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P,
et al. Identification of citrullinated -enolase as a candidate
autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:
R1421–9.
14. Van Steendam K, Tilleman K, De Ceuleneer M, De Keyser F,
Elewaut D, Deforce D. Citrullinated vimentin as an important
antigen in immune complexes from synovial fluid of rheumatoid
arthritis patients with antibodies against citrullinated proteins.
Arthritis Res Ther 2010;12:R132.
15. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij
WJ, Tak PP. The presence of citrullinated proteins is not specific
for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485–94.
16. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R,
Mechin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and
PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in
rheumatoid arthritis synovium in close association with tissue
inflammation. Arthritis Rheum 2007;56:3541–53.
17. Korchynskyi O, ten Dijke P. Identification and functional charac-
terization of distinct critically important bone morphogenetic
protein-specific response elements in the Id1 promoter. J Biol
Chem 2002;277:4883–91.
18. Senshu T, Sato T, Inoue T, Akiyama K, Asaga H. Detection of
citrulline residues in deiminated proteins on polyvinylidene diflu-
oride membrane. Anal Biochem 1992;203:94–100.
19. Tsuji Y, Akiyama M, Arita K, Senshu T, Shimizu H. Changing
pattern of deiminated proteins in developing human epidermis.
J Invest Dermatol 2003;120:817–22.
20. Kubota K, Yoneyama-Takazawa T, Ichikawa K. Determination of
sites citrullinated by peptidylarginine deiminase using 18O stable
isotope labeling and mass spectrometry. Rapid Commun Mass
Spectrom 2005;19:683–8.
21. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK
III, et al. CXCL16-mediated cell recruitment to rheumatoid
arthritis synovial tissue and murine lymph nodes is dependent
upon the MAPK pathway. Arthritis Rheum 2006;54:765–78.
22. Ruth JH, Arendt MD, Amin MA, Ahmed S, Marotte H, Rabquer
BJ, et al. Expression and function of CXCL16 in a novel model of
gout. Arthritis Rheum 2010;62:2536–44.
23. Koch AE, Burrows JC, Marder R, Domer PH, Leibovich SJ.
Reactivity of human tissues with monoclonal antibodies to myeloid
activation and differentiation antigens: an immunohistochemical
study. Pathobiology 1990;58:241–8.
24. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de
Putte LB, van Riel PL. Modified disease activity scores that
include twenty-eight–joint counts: development and validation in a
prospective longitudinal study of patients with rheumatoid arthri-
tis. Arthritis Rheum 1995;38:44–8.
25. Wuyts A, Govaerts C, Struyf S, Lenaerts JP, Put W, Conings R, et
al. Isolation of the CXC chemokines ENA-78, GRO  and GRO
 from tumor cells and leukocytes reveals NH2-terminal hetero-
geneity: functional comparison of different natural isoforms. Eur
J Biochem 1999;260:421–9.
26. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA,
Gimbrone MA, et al. MCP-1 and IL-8 trigger firm adhesion of
monocytes to vascular endothelium under flow conditions. Nature
1999;398:718–23.
27. Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S,
et al. Citrullination of CXCL8 by peptidylarginine deiminase alters
receptor usage, prevents proteolysis, and dampens tissue inflam-
mation. J Exp Med 2008;205:2085–97.
28. Loos T, Opdenakker G, Van Damme J, Proost P. Citrullination of
CXCL8 increases this chemokine’s ability to mobilize neutrophils
into the blood circulation. Haematologica 2009;94:1346–53.
29. Loos T, Mortier A, Gouwy M, Ronsse I, Put W, Lenaerts JP, et al.
Citrullination of CXCL10 and CXCL11 by peptidylarginine deimi-
nase: a naturally occurring posttranslational modification of
chemokines and new dimension of immunoregulation. Blood
2008;112:2648–56.
30. Struyf S, Noppen S, Loos T, Mortier A, Gouwy M, Verbeke H, et
al. Citrullination of CXCL12 differentially reduces CXCR4 and
CXCR7 binding with loss of inflammatory and anti-HIV-1 activity
via CXCR4. J Immunol 2009;182:666–74.
31. Chang X, Zhao Y, Sun S, Zhang Y, Zhu Y. The expression of
PADI4 in synovium of rheumatoid arthritis. Rheumatol Int 2009;
29:1411–6.
32. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines
GK, et al. Enhanced production of monocyte chemoattractant
protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772–9.
33. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK,
Burdick MD, et al. Macrophage inflammatory protein-1 : a novel
chemotactic cytokine for macrophages in rheumatoid arthritis.
J Clin Invest 1994;93:921–8.
34. Akahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K,
et al. Expression of monocyte chemotactic and activating factor in
rheumatoid arthritis: regulation of its production in synovial cells
by interleukin-1 and tumor necrosis factor. Arthritis Rheum
1993;36:762–71.
35. Hatano Y, Kasama T, Iwabuchi H, Hanaoka R, Takeuchi HT, Jing
L, et al. Macrophage inflammatory protein 1  expression by
synovial fluid neutrophils in rheumatoid arthritis. Ann Rheum Dis
1999;58:297–302.
36. Peichl P, Ceska M, Effenberger F, Haberhauer G, Broell H,
2726 YOSHIDA ET AL
Lindley IJ. Presence of NAP-1/IL-8 in synovial fluids indicates a
possible pathogenic role in rheumatoid arthritis. Scand J Immunol
1991;34:333–9.
37. Mortier A, Gouwy M, Van Damme J, Proost P. Effect of post-
translational processing on the in vitro and in vivo activity of
chemokines. Exp Cell Res 2011;317:642–54.
38. Mortier A, Loos T, Gouwy M, Ronsse I, Van Damme J, Proost P.
Posttranslational modification of the NH2-terminal region of
CXCL5 by proteases or peptidylarginine deiminases (PAD) dif-
ferently affects its biological activity. J Biol Chem 2010;285:
29750–9.
39. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD,
Kasper J, et al. The functional role of the ELR motif in CXC
chemokine-mediated angiogenesis. J Biol Chem 1995;270:
27348–57.
40. Koch AE, Volin MV, Woods JM, Kunkel SL, Connors MA,
Harlow LA, et al. Regulation of angiogenesis by the C-X-C
chemokines interleukin-8 and epithelial neutrophil activating pep-
tide 78 in the rheumatoid joint. Arthritis Rheum 2001;44:31–40.
41. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and
functional expression of a human interleukin-8 receptor. Science
1991;253:1278–80.
42. Murphy PM, Tiffany HL. Cloning of complementary DNA encod-
ing a functional human interleukin-8 receptor. Science 1991;253:
1280–3.
43. Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J,
et al. Expression of the neutrophil-activating CXC chemokine
ENA-78/CXCL5 by human eosinophils. Clin Exp Allergy 2003;33:
531–7.
44. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev
2001;12:313–35.
45. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D,
Fine JS. CXCR2 antagonists for the treatment of pulmonary
disease. Pharmacol Ther 2009;121:55–68.
46. Browning DD, Diehl WC, Hsu MH, Schraufstatter IU, Ye RD.
Autocrine regulation of interleukin-8 production in human mono-
cytes. Am J Physiol Lung Cell Mol Physiol 2000;279:L1129–36.
47. Ludwig A, Petersen F, Zahn S, Gotze O, Schroder JM, Flad HD,
et al. The CXC-chemokine neutrophil-activating peptide-2 in-
duces two distinct optima of neutrophil chemotaxis by differential
interaction with interleukin-8 receptors CXCR-1 and CXCR-2.
Blood 1997;90:4588–97.
48. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R,
Matsushima K, et al. International union of pharmacology. XXII.
Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:
145–76.
49. Snir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, et
al. Identification and functional characterization of T cells reactive
to citrullinated vimentin in HLA–DRB1*0401–positive humanized
mice and rheumatoid arthritis patients. Arthritis Rheum 2011;63:
2873–83.
50. Fan LY, He DY, Wang Q, Zong M, Zhang H, Yang L, et al.
Citrullinated vimentin stimulates proliferation, pro-inflammatory
cytokine secretion, and PADI4 and RANKL expression of fibro-
blast-like synoviocytes in rheumatoid arthritis. Scand J Rheumatol
2012;41:354–8.
51. Liddiard K, Rosas M, Davies LC, Jones SA, Taylor PR. Macro-
phage heterogeneity and acute inflammation. Eur J Immunol
2011;41:2503–8.
CITRULLINATED ENA-78/CXCL5 IN RHEUMATOID ARTHRITIS 2727
